Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and ...

DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...

The FDA has approved Dexcom's G7 wearable for glucose monitoring for people with all types of diabetes, and the company expects it hit pharmacy shelves in 2023. The wearable is now cleared in the US ...

DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

The U.S. Food and Drug Administration has announced a recall of specific Dexcom (NASDAQ:DXCM) glucose monitoring devices, including the G6, G7, ONE, and ONE+ models. The recall is due to a potential ...